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Abstract Acute lymphoblastic leukemia (ALL) is a
malignant disease characterized by an uncontrolled pro-
liferation of immature lymphoid cells. ALL is the most
common hematologic malignancy in early childhood, and
it reaches peak incidence between the ages of 2 and
3 years. The prognosis of ALL is associated with aberrant
gene expression, in addition to the presence of numerical or
structural chromosomal alterations, age, race, and
immunophenotype. The Relapse rate with regard to phar-
macological treatment rises in childhood; thus, the
expression of biomarkers associated with the activation of
cell signaling pathways is crucial to establish the disease
prognosis. Intracellular pathways involved in ALL are
diverse, including Janus kinase/Signal transducers and
transcription activators (JAK-STAT), Phosphoinositide-3-
kinase–protein kinase B (PI3K-AKT), Ras mitogen-acti-
vated protein kinase (Ras-MAPK), Glycogen synthase
kinase-3b (GSK-3b), Nuclear factor-kappa beta (NF-jB),
and Hypoxia-inducible transcription factor 1a (HIF-1a),
among others. In this review, we present several thera-
peutic targets, intracellular pathways, and molecular
markers that are being studied extensively at present.
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Introduction
The acute leukemia is the most common cancer in children,
adolescents, and young adults. These diseases are charac-
terized by great clinical variability, prompting an on-going
search for accurate outcome predictors. Using algorithms
based on clinical manifestations at presentation, response
to therapy, and several molecular analyses, some patients
are diagnosed with the features of high-risk disease and are
at comparatively greater risk for relapse [1].
Molecular analyses of patients with high-risk acute
leukemia have resulted in an improved understanding of
how deregulated cellular signaling can affect resistance to
conventional therapy. In this regard, molecular therapies
that target genetic abnormalities in leukemic cells and their
affected signaling pathways have been emerging in pedi-
atric Acute lymphoblastic leukemia (ALL). Expression
profiling, whole-genome sequencing, and other molecular
analyses have provided insight into the signaling pathways
that are mechanistically related to chemotherapy resis-
tance. For pediatric acute leukemia, the molecular deter-
minants of risk have yet to be fully defined, and target
therapies remain in the earliest stages of discovery [1].
Whereas exciting discoveries continue to be made in the
identification of relevant molecular biomarkers and tar-
geted therapies, the challenges and opportunities associated
with these findings continue to await being clearly defined
in future clinical trials [1].
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Acute Lymphoblastic Leukemia
The clinical presentation of ALL is variable with an
insidious initial manifestation of about 4 weeks. This
type of leukemia is more common in early childhood,
and reaches its highest incidence between the ages of 2
and 3 years ([80 per million per year, pmpy), with rates
decreasing to 20 pmpy in children between 8 and
10 years. In many cases, some leukemic cells have
begun to accumulate in different organs such as the
liver, lymph nodes, spleen and central nervous system
(CNS) when the diagnosis is confirmed [1]. The com-
plete blood count generally reflect marrow failure con-
ditioned by the invasion of leukemic cells such as
anemia, thrombocytopenia and neutropenia, therefore, in
the study of acute leukemia, morphology and cyto-
chemical stains are essential in the initial characteriza-
tion of the disease [1, 2].
The genetic basis of this disease has been revolutionized
with the study of long cohorts [2]. The identification of new
ALL subtypes, structural and numerical genetic alterations,
transcriptomic profile, key genes in outcome and resistance
to the treatment are critical keys to redefine the ALL
classification in the shortcoming time [2, 3].
Classification and Staging
French- American -British (FAB) Classification
Cell morphology criteria classifies ALL as L1, L2 and L3
based on the characteristics of the leukemic cell. Approx-
imately 70–85 % of all enrolled pediatric patients belong to
the ALL L1 group. While the morphological distinction
between L1 and L2 variety losses prognostic value, the L3
morphology has been associated with the mature B- range
[2].
Risk Groups in Childhood ALL
Children with ALL are classified into four risk groups
according to the National Cancer Institute (NCI): very
high, high, standard and lower risk [4].Participants of a
recent workshop sponsored by the NCI defined standard-
risk ALL as B-precursor cases with age between one and
10 years and an initial leukocyte count of \50 9 109/L.
All other patients are considered high-risk [4].
The type of leukemia determines the initial response to
treatment; therefore, the predictive factors have a very
important role in childhood acute lymphoblastic leukemia
(chALL) (Table 2) [3, 5].
Leukemic Cells Immunophenotype
The immunophenotype is a highly significant prognostics
feature. With this diagnostic method, the target is to
identify the affected cell line, whether B or T. Children
with acute pre-B cell leukemia or early pre-B cell leukemia
early respond better than those with T-cell leukemia and
mature B-cell leukemia [6–10].
The prognostic significance of cell surface markers in
ALL is an integral and important part of disease diagnosis,
classification, and prognosis. These cells have been clas-
sified by mature, differentiation, and activation markers,
according to the expression of these surface markers: for
example, CD45 is a blastic cell marker, CD34, CD117,
HLA-DR, and TdT are mature cell markers, CD10, CD19,
CD20, CD22, and CD79A are B-lymphoid lineage mark-
ers, and CD1a, CD2, CD3, CD5, and CD7T- are lymphoid
lineage markers.
The previously mentioned cell surface markers have
been correlated with the prognosis in ALL; accordingly,
early T-precursor ALL and T-ALL demonstrate poorer
prognosis than B-cell lineage leukemia [5, 11, 12]. Simi-
larly, the presence of CD20 has been associated with a high
WBC count and a lower platelet count [12].
Cytogenetic Abnormalities
The cytogenetic abnormalities include an important num-
ber of structural and numerical alterations present in
chALL. According with the World Health Organization
(WHO) the classification of acute leukemia includes two
lineages; B lymphoblastic leukemia and T lymphoblastic
leukemia (Table 1) [13].
Leukemic cells are usually associated with an increased
number of chromosomes (hyperdiploid), the most common
of this phenomenon affects the 4, 10, 17, and 18 chromo-
somes; moreover, leukemic cells can also be associated
with a decreased number of chromosomes related with a
poor prognosis. In fact, a translocation between chromo-
somes 12 and 21 t(12;21) is more likely to be cured [13].
On the contrary, children with a translocation between
chromosomes 9 and 22, or between 1 and 19, have a lower
cure rate. Children with a translocation affecting chromo-
somes 4 and 11 or all (q23) translocations also have a lower
cure rate [5, 14, 15]. Chromosomal translocations that
possess prognostic significance may be detected in a sub-
stantial number of cases of pediatric ALL, and some of
these rearrangements are described later.
Cryptic translocation t(12;21) favors the fusion of TEL
(ETV6) gene on chromosome 12 to the AML1(CBFA2)
gene on chromosome 21, resulting in the TEL-AML1 fusion
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that can be detected in 20–25 % of cases of B precursor
ALL, giving a favorable clinical outcome. Patients with
TEL-AML1 fusion, have a favorable clinical outcome,
although there is controversy concerning whether the final
cure rate is actually higher than that of other patients with
B-precursor ALL, or whether the final cure rate is similar,
but time-at-relapse occurs significantly later in patients
with TEL-AML1 fusion compared with other patients with
B-precursor ALL.
Linka et al. [16] recently identified, directly and indi-
rectly, regulated target genes with an inducible design TEL-
AML1 system to explain the mechanism associated with
cellular proliferation and transport, cellular migration, and
stress responses in chALL. Therefore, the Philadelphia
chromosome (Ph chromosome) implicates the t(9;22)
translocation that is present in approximately 4 % of
pediatric ALL which confers a poor prognosis, especially
when associated with either a high WBC count or a slow,
early response to initial therapy. The Ph chromosome is
more common among older patients with B-precursor ALL
and high WBC count [13].
Another translocation involved in chALL is the t(11;19)
that occurs in about 1 % of cases B or T precursors. The
t(11;19) have a worse prognosis but the result appears
relatively favorable for children with T-cell ALL and the
t(11;19) [14, 15].
Finally, t(1;19) presents in 5–6 % of cases of chALL,
and consists of E2A gene to the PBX1 gene fusion located
on chromosome 19 and 1 respectively. t(1;19) could pre-
sent either as an unbalanced translocation or as primarily
associated with pre-B ALL (cytoplasmic immunoglobulin-
positive). E2A-PBX1 fusion was initially associated with
inferior outcome in the context of antimetabolite-based
therapy [5]. It has been demonstrated that the poor prog-
nosis associated with t(1;19) can be largely overcome by
more intensive therapy. However, improvement in the
results appears to be primarily for patients with t(1;19)
who, whether unbalanced and balanced; remain at higher
risk of treatment non-response [14].
Intracellular Signaling Pathways and Outcome
The outcome for children with ALL is determined by a
variety of clinical and laboratory variables. Risk stratifi-
cation provides a tool to adjust the treatment, avoiding
intensive therapies or unnecessary dose escalation for
patients with a favorable prognosis. However, there is an
important percentage of patients who have been classified
with low risk, but they present relapse; currently, despite
the use of multiple, independent prognostic features to
assess the chance for relapse, approximately one half of
patients who relapse are found to have favorable clinical
features and an excellent response to induction therapy.
Hence, the search for additional variables is necessary to
redefine risk stratification [17]. The emergence of resistant
clones poses a difficult challenge regardless of the previous
treatment intensity [14]. It is possible that the size of a
resistant subclone will determine whether a patient fails
induction or has an early relapse, and also may govern
ease-of-identification of an underlying high-risk molecular
feature [18]. At present, a redefinition of risk stratification
has been proposed based on the study of altered genes
during oncogenesis [17, 18]. Actually, a redefinition of risk
stratification has been proposed based on the study of
altered genes during oncogenesis [17].
JAK-STAT Pathway
The JAK-STAT pathway consists of Janus family protein
tyrosine kinases JAK1, JAK2, JAK3 and and TYK2 and a
family of seven cytosolic transcription factors, and made
up of STAT (Signal transducers and transcription activa-
tors), a complex of six subtypes including 1, 2, 3, 4, 5a, 5b,
and 6 with the same activation process mediated by cyto-
kine and other stimuli. Several hematologic malignancies
appear to be driven by molecular aberrations that affect the
JAK-STAT pathway, including JAK2 and JAK1 mutations
[19, 20], leading to the targeted development of small
molecules that might control deregulated signaling [21].
Table 1 WHO classification of
acute leukemia
B lymphoblastic leukemia/lymphoma
B lymphoblastic leukemia/lymphoma, NOS
B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities
B lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2);BCR-ABL 1
B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22) TEL-AML1 (ETV6-RUNX1)
B lymphoblastic leukemia/lymphoma with hyperdiploidy
B lymphoblastic leukemia/lymphoma with hypodiploidy
B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32) IL3-IGH
B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1
T lymphoblastic leukemia/lymphoma
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JAK mutations have been described in high-risk chALL;
in mutated cases a gene expression signature similar to
BCR-ABL pediatric ALL had been identified. The results of
Mullighan et al. suggest that JAK signaling inhibition is a
target for therapeutic intervention in JAK mutated ALL; the
authors reported activating mutations in JAK1 [3], JAK2
[16], and JAK3 [1], which represent 10.7 % of high-risk
chALL cases negative to BCR-ABL [22].
Patients with JAK mutations have a poor outcome; the
primary structure of JAK 1, -2 and -3 exhibit different
changes; including missense, insertions and deletion
mutation [21]. JAK1 is activated by a wide variety of
cytokines; JAK 1, -2 and -3 are ubiquitously expressed and
interact with many different cytokine receptors [23–26].
Based on this data, JAK inhibitors could be used in these
hematological diseases, in that they avoid the proliferation
of malignant cells [27, 28].
JAK1 in Cytokine-Induced Biologic Responses
Associated with chALL
JAK1 affects a wide variety of interleukins (IL), including
IL-2, -4, -6, -7, -9, -10, -15, the Leukocyte inhibitory factor
(LIF) and all interferons that participate in the hemato-
poiesis process; JAK1 mutations impair lymphoid devel-
opment and defective responses to class 2 cytokines and
those using gp130 receptor subunits [21, 23]. Cytokines
that bind to class I or class II cytokine receptors employ the
JAK-STAT signaling pathway [23].
JAK2 in Cytokine Responses and Erythropoietin
Receptor Activity
Janus-kinase 2 (JAK2) is required for the function of a
variety of cytokine receptors. In addition, the mutations of
JAK2 affects the erythropoiesis process and inhibits the
correct evolution [29]. Initial studies that suggested the
JAK2-EPO relation reported an important number of
kinases that have been implicated in signaling [30]. JAK2
gives rise to a regulator effect in EPO, Thrombopoietin
(TPO), IL-3, IL-5, (GM-CSF), and Interferon gamma (IFN-
c) expression [29, 31].
JAK2 is constitutively bound to cell surface erythro-
poietin receptor (EpoR) and is crucial in signaling that
include the growth hormone receptor [32]. JAK2 is crucial
for EpoR signaling; JAK2 phosphorylated tyrosine residues
in EpoR cause docking sites for SH2 and subsequently the
activation of STAT5, Ras, mitogen-activated protein kinase
(MAPK), JNK, P38, PI3-kinase–AKT, SHP1, SHP2, SHIP,
and BCL-xL [33].
A JAK2 inhibitor such as Ruxolitinib has been reported
as an active therapeutic in preclinical models of Poly-
cythemia vera (PV) and other myeloproliferative
neoplasms associated with somatic gain-of-function JAK2
mutations [34].
The fusion of JAK2 to PCM1 is a product of the
translocation t (8; 9)(p22; p24); an uncommon case clas-
sified as myeloid and lymphoid neoplasms with eosino-
philia and abnormalities of PDGFRA, PDGFRB or
FGFR1, in this case there are an aberrant tyrosine kinase
expression [35].
Yu et al. [36, 37] tested JAK2 inhibitors with a purified
enzyme assays in a high-throughput using a line of Ba/F3
cells that expressing individually the translocated ETS
leukemia (TEL) fusions of each JAK family member
(TELJAK Ba/F3). This technique should provide a more
meaningful understanding of selectivity and facilitate the
development of additional JAK inhibitors.
JAK3 in the Lymphoid Development
JAK3 mutations are associated with defective lymphoid
development, deregulated myelopoiesis, and the affectation
of different cytokines, such as IL-4, -7, -9, and -15 [38, 39].
Signaling regulation of proliferation and apoptosis by
JAK3 has been found in the physiopathology of different
leukemia types, including acute megakaryoblastic leuke-
mia and T-cell lymphoma, and PEPT1 and -2 (peptide
transporters) are regulated by JAK3, a powerful regulator
of these peptide transporters [40].
Ross et al. [41] have tested JAK3 inhibitors considering
the important role of JAK3 in T-cell malignancies,
including T-cell ALL (T-ALL), and the authors used a
selective and orally active small molecule with high rates
of effectiveness to induce therapeutic response in T-cell
malignancies with less toxic therapies.
Mutations in receptor of Interleukin 7 (IL7R) and others
altered cytokine IL-7 stimulate the differentiation of multi-
potent hematopoietic stem cells (HSC) from lymphoid
lineage. The receptor of Interleukin 7 (IL-7R) which is
formed by IL-7Ra (encoded by IL-7R) is essential for
normal T-cell development and homeostasis [42]. IL-7
plays an important role in the development and home-
ostasis of cells and is involved in the proliferation, matu-
ration and survival of of B, T and Natural Killer (NK) cells
(Table 2).
Ott et al. [43] have investigated the chemical compound
JQ1 as possible therapeutic option as it reduces the via-
bility of B-ALL cell line through the BET protein inhibi-
tion especially in patients with high-risk cytogenetic.
Therefore plasma concentration of IL-2 receptor, IL-8, -12
and -15 or C–X–C motif chemokine 10 (CXCL10) in pri-
mary myelofibrosis is important due to their association
with prognostic. In addition to these cytokines, IL-10 and
CXCL9 have been included in the prognosis of large-cell
lymphoma [44, 45].
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Signaling of TYK2 in ALL
Tyk2 is the last JAK family member with an effect medi-
ated by. Recently, Sanda et al. [46] utilized RNA inter-
ference (RNAi) to identify the TYK2-STAT1 pathway in
T-ALL, promoting it as a novel oncogenic pathway that
upregulates BCL2 expression.
STATs
STAT is a protein complex with an important role in the
regulation of hematopoiesis mediated by cytokine signal
transduction [47, 48]. The majority of critical processes are
regulated by STAT, including cellular proliferation and
survival. To our knowledge, STAT activation is mediated
by a receptor complex, and it translocates to modify
nuclear gene expression [21].
STAT1
A region required of the EpoR for the STAT1 has been
identified in a JAK2 dependent process; this transcription
factor is activated after EPO treatment and is mediated by
the Tyr 432 residue of the human EpoR gene, suggesting its
role in the development of normal erythropoiesis [47].
Thus, Interferon (INF) and innate immune responses are
associated with the regulation of STAT1 expression [21].
STAT2
Alterations in STAT2 affect the type 1 INF response [21].
STAT3
STAT3 inhibitors have been employed with high effec-
tiveness levels in cellular lines. STAT3 plays an important
role in signaling pathways related with oncogenic pro-
cesses. Despite that in normal cells STAT inhibitors do not
demonstrate significant effects, they continue to be
molecular targets in malignant cells [48]. In other hema-
tological disorders that affect myeloid linage, the BCR-
ABL activates STAT3 in human cells mediated by the JAK
pathway including MEK. Coppo et al. [49, 50] established
that the activation mechanism of STAT3 has been medi-
ated by JAK and Erk/MAP-kinase, leading to the increase
of STAT3 mRNA, which should contribute to CML pro-
gression and to increased risk in patients with the Ph
chromosome.
STAT4
This STAT is associated with IL-12 response, IFN c-Ra
production by Th1 cells, lymphocyte proliferation, and
other Th2 cell responses [21].
Table 2 chALL characteristics of risk
Characteristics of risk disease Precursor B-Cell T-linage ALL
Age at presentation \1 year,[10 years [10 years
Initial WBC count [50,000
Extramedullary disease CNS/Testes CNS/Testes
Phenotypic subset Early T-precursor and mixed phenotype
acute leukemia. (ETP/MPAL)
Common karyotype abnormalities t(9;22), (q34;q22), rearranged MLL, hypodiploidy
(\0.84)
Complex anomalies
Common gene mutations FLT3/ITD, BCR/ABL, CRLF2, JAK1, JAK2, IKZF ABD, ME2KC, IL-7R
Expression profiling signatures
revealing target-able pathways.
Overexpression of PI3K-AKT, RAS-MAPK, BCR-
ABL-like
Dysregulation TGFb1, G0/G1 cell, cycle
arrest
Clinic presentation Frequent fever
Hepatosplenomegaly and lymphadenopathy as an




Blasts morphology Small, large core, scant cytoplasm homogeneous
chromatin
Prognosis Standard risk: 85 %, High risk: 75 %, Infants\50 %
Immunophenotype CD10, CD19, CD22, TdT CD2, CD3, CD5, CD7, TdT
CNS central nervous system
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STAT5 a/b
STAT5 a/b affects the proliferation signaling, including
CFU-Mix, Eos, G, GM, and the absence of NK cells [21].
The active forms, A and B, are mediators of the oncogenic
process that utilize a similar mechanism to that of STAT3.
In essays employing Pimozide to evaluate the in vitro
colony formation of healthy cells, there have been favor-
able results without hematopoietic toxicity. STAT5 is
associated with a normal hematopoiesis process mediating
cytokine responses; this latter notion supports the concept
that healthy cells are not affected by STAT5 inhibitors, an
interesting target in ALL [48].
STAT6
Mutations of this STAT have been identified in cases of IL-
4 response failure; these Th2 cell affectations should be
reduced simultaneously the lymphocyte proliferation [21].
In fact, in mice models the induction of STAT6 deficiencies
affect the biological responses in B cells associated with
IL-4 levels [51].
The PI3K-AKT/Ras-MAPK Pathway
RAS proteins are regulated by guanine-nucleotide-ex-
change factors prior to stimulation of the nucleotide pro-
cess. Mitogen-activated protein kinase (MAPK) and
Phosphatidylinositol 3-kinase (PI3K) pathways are regu-
lated by the formation of an intracellular docking site able
to regulate cell proliferation, organization, and survival
[52].
The RAS gene family includes KRAS, HRAS, and NRAS
genes with similar effects in the development of cell cycle,
although Ras genes have specific differences due to the
presence of a posttranslational modification [52].
The PI3K-AKT and Ras-MAPK prosurvival signaling
pathways are required for normal homeostasis in nonma-
lignant cells, but there is a continued reliance or ‘‘addic-
tion’’ by leukemia cells on these pathways that has made
them popular for targeted therapies. The PI3K-Akt path-
way is often constitutively upregulated in many lymphoid
malignancies (reviewed by Lee-Sherick et al.) [53], leading
to the development of targeted therapies against the
mammalian Target of Rapamycin (mTOR) and the TOR
complexes [54, 55]. Inhibition of mTOR has been found to
be effective in pediatric ALL [55].
The interaction between the PI3K-Akt pathway and
the active forms STAT5a and STAT5b is mediated by
Grb2 growth factor receptor bound protein 2 (Grb2).
There are two different important roles of Gab2 in
hematological disorders; Gab2 is associated with the
activation PI3K/Akt and Ras/MAPK pathway mediated
by STAT5 protein activation, and with ERK and Akt
activation [56].
Inhibition of the PI3K/AKT/mTOR pathway has been a
therapeutic tool in ALL; unfortunately, resistance to ther-
apy is emerging. The use of selective inhibitors of this
pathway, such as NVP-BKM120, RAD001, BEZ235, and
NVP-BGT226, were compared in the cell cultures of ALL
cells and probed in an experimental design; in this case, the
combined use of dual PI3K/mTOR inhibitors provided an
interesting therapeutic approach, especially in patients with
the ALL linage of pre-B cells [57].
Glycogen Synthase Kinase-3b (GSK-3b)—NF-jB
Pathway
Glycogen synthase kinase-3b (GSK-3b) has recently been
found to positively regulate the activity of Nuclear factor-
kappa B (NF-jB). The association between GSK-3b inhi-
bition and NF-jB has been studied in pediatric primary
leukemia cells obtained from newly diagnosed children
with ALL. Hu et al. [58] isolated Bone marrow mononu-
clear cells (BMMC) by density gradient centrifugation
from the heparinized aspirates of children with ALL. This
group utilized immunofluorescence staining to detect
nuclear GSK-3b in these cells, as well as western blot and
electrophoretic mobility shift assays, testing the GSK-3b
inhibitor in vitro treatment. By using this approach, these
authors showed that inhibition of GSK-3b downregulates
the NF-jB activation pathway, leading to suppression of
the expression of an NF-jB-regulated gene and the pro-
motion of apoptosis in ALL cells in vitro.
Therefore, GSK-3b is a multi-faceted kinase that is
regulated by different growth factor signaling pathways
and that affects a diverse range of physiological processes.
Although crosstalk among signaling pathways is a feature
of development, homeostasis, and disease, it is widely
accepted that the Wnt pathway is associated with other
signaling pathways: in Wnt-stimulated cells, inhibition of
GSK-3b exerts a profound influence on b-catenin and Axin
phosphorylation, but does not substantially affect the
phosphorylation of other GSK-3b target substrates, such as
tau and glycogen synthase [59].
The mTOR and GSK-3b cooperate to control the
activity of S6K1, an important regulator of cell prolifer-
ation and growth [60]. The 40S ribosomal protein S6
kinase (S6K) is a major substrate of mTOR and is a crucial
effector of mTOR signaling [61]. One of the S6 K iso-
forms, S6K1, plays important roles in cell growth, pro-
liferation, and cell differentiation by regulating ribosome
biogenesis, protein synthesis, cell cycle progression, and
metabolism [62, 63].
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Hypoxia-Inducible Transcription Factor-1a (HIF-
1a)—GSK-3b Pathway
Hypoxia-inducible transcription factor-1a (HIF-1a) is a
major regulator of carcinogenesis and various processes by
which cells adapt to hypoxic conditions, being an important
target for the understanding of angiogenesis and different
cancer phenotypes and for unraveling new therapeutic
options [61]. Flüel et al. [64] proposed an interactive
mechanism between HIF-1a and GSK-3 across induced
phosphorylation and recruitment of the ubiquitin ligase and
tumor suppressor F-box and WD protein Fbw7.
CBFA2/RUNX1
RUNX1 is a runt-related transcription factor 1 also known
as CBFA2 (corebinding factor a2) or AML1 (acute myel-
ogenous leukemia 1). RUNX1 is a heterodimeric tran-
scription factor with multiple splice variants that plays a
role in normal hematopoiesis. Defects in RUNX1 are
associated with several types of leukemia.
At present, detection of human RUNX1/CBFA2 by
Western blot comprises a necessary tool to determine this
frequent translocation variant between intron 5 of TEL and
intron 2 of AML [65].
Mutations in RUNX1 have been identified in T-ALL.
Dowdy et al. [66] induced triple-point mutations in mouse
model to characterize the effects in different hematopoietic
lineages. In this case, induction with a RUNX1 HTY350-
352AAA causes several alterations in embryonic devel-
opment mediated by a mechanism related with transacti-
vation and co-factor interaction TGF (Tumor growth
factor)-b/BMP pathway. In specific domains of RUNX1,
mutations have been reported that provide abnormal sub-
nuclear targeting and interaction with co-factor processes,
inducing alterations in early stages of hematopoiesis and
leading to a pre-leukemic phenotype; this punctual muta-
tion is induced by RUNX1 HTY350-352AAA, and the
results indicate the crucial role of this transcription factor
in the control and development of definitive hematopoiesis
at different stages and its importance as a therapeutic
target.
Moreover, RUNX1 is not exclusively associated with
ALL, as it is also important in myeloid neoplasm sup-
pression. In mouse model, overexpression of RUNX1
inhibited the growth of normal umbilical cord-blood cells
and promoted the growth of AML1-ETO. These results are
promising for AML treatment [67].
Lymphoid Transcription Factor IKZF1 (IKAROS)
The lymphoid transcription factor IKZF1 (IKAROS) has
been associated with poor outcome in patients with ALL.
Currently, determination of abnormalities in IKZF1 and
other genes by multiplex ligation-dependent probe ampli-
fication contributes to promoting the physiopathology and
prognosis of the disease [68].
HOXA Cluster
HOX genes have importance in normal development of
lymphopoiesis and leukemogenesis processes and there are
two classes of HOX genes class I and class II. The first
group includes four clusters (HOXA, HOXB, HOXC and
HOXD) and the second group TLX1 and TLX3. HOXA,
TLX1 and TLX3 have been strongly associated with T-
ALL development [15, 69].
Starkova et al. [69] analyzed 61 pediatric samples with
ALL diagnosis and quantified RNA expression of HOX
genes associated with ALL development: HOXA, HOXB,
and CDX1/2 using qRT-PCR. Considering the diagnosis,
the patients were analyzed in karyotype subgroups; in
BCP-ALL and T-ALL patients expressed HOXA 3–4,
HOXA 7, and HOXB 3–4 genes including abnormal kary-
otype as MLL/AF4, TEL/AML1 and BCR/ABL. In immature
cells and progenitors were identified HOXA 7–10, 13 and
HOXB 2–4, moreover HOXB 6 and CDX 2 were detected
only in leukemic cells. Therefore, they found a particular
expression in each karyotype anomaly. Information related
to the most common caryotype associated to chALL is
shown in Table 3.
Abnormal expression of HOXA9 has been correlated
with the development of T-cell and myeloid leukemia.
However, the study of overexpression in hematopoietic
tissues demonstrated the HOXA9 role in accelerated lym-
phoid, but not in myeloid, leukemia. Transformation uti-
lizing Vav regulatory elements in mouse model has
provided valuable information about the overexpression of
other HOXA cluster genes; however, lower levels of
HOXA9 stimulate the development of a T-cell precursor to
lymphoblastic leukemia [70]. Finally, HOX11 activation
has been associated with a favorable prognosis in T-ALL
[71].
LMO1 and LMO2
The presence of chromosomal rearrangements in ALL is
common: LMO1 and LMO2 overexpression in the loci of
the T-cell receptor has been found at around 45 % of total
cases. Therefore, LMO1 and -2 encode in the LIM-domain:
11p15 and 11p13, respectively. LMO proteins are associ-
ated with LYL1 or TAL1 dysregulation and the latter is
associated with the induction of T-cell malignancies in co-
expression with TAL1 [15, 72]. LMO2 has been associated
with other chromosomal aberrations, specifically with
TAL1 in a same cluster, suggesting that LMO2 and TAL1
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rearrangements affect similar pathways. In a cohort of 117
samples of patients with an ALL diagnosis, Homminga
et al., by Fluorescent in situ hybridization (FISH) and real-
time quantitative PCR (RQ-PCR), the authors found, in
their results, that LYL1 translocation and LMO2 rear-
rangement conform a TAL-LMO subgroup present in
immature cells [73]. Moreover, LMO2 gene expression in
mouse model has been associated with the development of
T-ALL [74].
TAL1 and TAL2
TAL1 (also known as SCL) is not expressed in normal
T-cell development, but is rather a non-random genetic
defect in T-chALL; moreover, TAL1 gene expression in
mouse model has been associated with T-ALL develop-
ment [74]. TAL1/SCL activation in patients with ALL has
been identified in 50–60 % [71]. In leukemogenesis, the
TAL1/SCL product could interfere in E2A and HEB
transcriptional activity. Thus, Kusy et al. [75] character-
ized the oncogenic pathways associated with TAL1 acti-
vation, corroborating that in T-ALL cells, NKX3.1 is
activated by TAL1 in fusion with THE LMO-Ldb1 com-
plex, causing a suppression of heterochromatin protein 1
(HP1) and subsequently the NKX3.1 gene promoter, the
latter required for T-ALL proliferation. The authors con-
clude that TAL1 or NKX3.1 knockdown inhibit the
capacity of T-ALL cells to induce leukemia in mouse
model. TAL2 is not expressed in normal T-cell develop-
ment and promotes T-ALL [15, 76]. TAL2 is a helix-loop
helix protein, such as TAL1 and LYL1, and is a mediator
of T-cell leukemogenesis that is identified in T-ALL [77].
Lymphocyte-Specific Protein Tyrosine Kinase
(LCK)
Lymphocyte-specific protein tyrosine kinase (LCK) is
predominantly expressed in T cells. LCK gene location is
susceptible to chromosomal aberrations and, as a Src
family kinase member, it activity is regulated by tyrosine
phosphorylation at Tyr 394 and Tyr 505 [78]. LCK has
been associated with a deregulation of the tyrosine kinases
family and the regulation of the LIM domain. The con-
stitutive activation of LCK has been related with ALL and
other lymphoid malignancies. LCK regulates LMO2
expression and mediates a similar mechanism in the
nuclear Janus kinase 2 (JAK2). Overexpression of LCK is
implicated in hematological malignances [79].
TAN1/NOTCH1 and LYL1
NOTCH1 is another oncogene, like TAL1 and LMO2. In
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established through treatment with a vehicle of the c-sec-
retase inhibitor [74]. The role of NOTCH1 in the devel-
opment of T-ALL is mediated by its influence in signaling
pathways, encoding a transmembrane receptor on HSC that
induces proteolysis cleavage, allowing the intracellular-to-
nucleus translocation of NOTCH1 followed by the acti-
vation of HES1 (Hairy/enhancer of split) and Deltex
(DTX1), both present in about 50 % of T-ALL cases [52].
Furthermore, LYL1 is a basic Helix-loop-helix protein
(bHLH) that is non-expressed in normal T-cell lineages.
LYL1 ectopic expression is caused by juxtaposition on
chromosome 19 and chromosome 7 T-cell receptor t(7; 19).
The LYL1 structure contains a bHLH domain and a con-
served region with binding sites [80]. LYL1 is a tran-
scription factor that exhibits protein homology with TAL1,
which is also overexpressed in hematopoietic malignancies
[73].
In conclusion, there are under development at present an
extensive number of inhibitors of molecular targets asso-
ciated with intracellular signaling pathways in chALL
(Table 4). Throughout this review, we compiled informa-
tion on the main signaling pathways involved in ALL, one
of the most diverse and complex diseases that greatly affect
the child population in Mexico and worldwide.
The presence of fusion translocation products and other
cytogenetic abnormalities and their role as protein markers,
such as LMO1, LMO2, LCK, TAL1, TAL2, TAN1/
NOTCH1, LYL1, TCL1, and MYB, have already been
extensively described and are crucial to the understanding
and development of new therapies given its frequency in
the appearance of chALL.
Concerning the widely described and unconventional
intracellular signaling pathways, extensive evidence sup-
porting the key role of JAK-STAT pathway point muta-
tions in chALL pathophysiology provides the key to some
family members as oncogenic mediators against which are
directed the majority of therapeutic targets. However,
although the treatment response rate in pediatric population
is favorable at present, it is important to continue the
characterization of these, especially STAT3 and STAT5
transcriptional activity as JAK proteins effectors, including
the recently identified regulators of action.
Another important topic of lymphoid malignancy com-
prises the determination of molecular prognostic factors
that could establish the likelihood of relapse more accu-
rately, including the HOXA cluster. LYL1 and other pro-
teins implicated in cell maturation might be useful as
molecular risk factors, at least in T-cell malignancies.
NKX3.1 and its relationship with the TAL1 protein as
related with the proliferation of T-cells in ALL have gained
prominence for its role in leukemogenesis.
Finally, we must take GSK-3b inhibitors into account as
potential therapeutic targets, not only in hematologic
malignancies but also in metabolic processes, including
alterations in the signaling pathways of insulin and Alz-
heimer. Much research remains to investigate the
involvement of cellular pathways in leukemia, and proba-
bly a single molecule will not be the gold standard for
Table 4 Trials of therapeutic targets in ALL
Trial Mechanism/target Phase of trial/disadvantages Ref.
Recombinant human CD19L-
sTRAIL fusion protein
Heterogeneous expression of surface TRAIL
receptors in patients with B cell precursor
ALL.
Preclinical studies of CD19L-sTRAIL in
rodents/toxicity
[92]
mTOR inhibitors Decreased leukemia proliferation and growth
in pre B-ALL
Preclinical studies in mice models [54, 55, 57]
Preclinical setting treating individual patient-
derived ALL in vivo
[93]
Synergize with histone deacetylase inhibitors
to kill B-ALL.
Preclinical studies in Balb/c and C57Bl/6
mice
[94]
GSK-3b inhibitors Regulate the NF-jB transcriptional activity. Tests in cell culture obtained from bone
marrow mononuclear cells and mice
models/Drug toxicity
[58, 59]
Sphingosine kinase inhibitors Regulate the autophagy and apostosis in T-cell
ALL
Cell culture and primary samples [95]
Epigenetic drugs: histone 3
lysine 27 demethylases,
JMJD3 and UTX
The JMJD3 modulation affects the initiation
and maintenance of ALL, modulate H3K27
methylation
Tests in a knockout mouse models of
JMJD3 and UTX
[96]
VLA-5 blocking VLA-5 block may increase susceptibility to
therapy in BCL/ABL for Ph? ALL
treatment
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treatment or prognosis, but rather a mixed expression of
many of these.
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